Veliparib (ABT-888)

For research use only.

Catalog No.S1004 Synonyms: NSC 737664

131 publications

Veliparib (ABT-888) Chemical Structure

Molecular Weight(MW): 244.29

Veliparib (ABT-888) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Phase 3.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 156 In stock
USD 120 In stock
USD 227 In stock
USD 370 In stock
USD 617 In stock
USD 990 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Veliparib (ABT-888) has been cited by 131 publications

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Description Veliparib (ABT-888) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Phase 3.
Features Increases the efficacy of common cancer therapies such as radiation and alkylating agents.
Targets
PARP2 [1]
(Cell-free assay)
PARP1 [1]
(Cell-free assay)
2.9 nM(Ki) 5.2 nM(Ki)
In vitro

ABT-888 is inactive to SIRT2 (>5 μM). [1] ABT-888 inhibits the PARP activity with EC50 of 2 nM in C41 cells. [2] ABT-888 could decrease the PAR levels in both irradiated and nonirradiated H460 cells. ABT-888 also reduces clonogenic survival and inhibits DNA repair by PARP-1 inhibition in H460 cells. ABT-888 increases apoptosis and autophagy in H460 cells when combination with radiation. [3] ABT-888 also inhibits PARP activity in H1299, DU145 and 22RV1 cells and the inhibition is independent of p53 function. ABT-888 (10 μM) suppresses the surviving fraction (SF) by 43% in the clonogenic H1299 cells. ABT-888 shows effective radiosensitivity in oxic H1299 cells. Furthermore, ABT-888 could attenuate the SF of hypoxic-irradiated cells including H1299, DU145 and 22RV1. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
C41 NEDFco5McW6jc3WgRZN{[Xl? MnTPN|AhdWmw MUjJcohq[mm2aX;uJI9nKFCDUmCxJJdqfGhiRVO1NEBw\iByLkCwNkDPxE1? M1T4S|E6QDh6N{[w
Jurkat Ml2xT4lv[XOnIFHzd4F6 Mn\mPVYhcA>? MoTNSG1UVw>? M{Ht[GlvcGmkaYTpc44hd2ZiUFHSVFEh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIH;mJINmdGxidnnhZoltcXS7IIfpeIghTUN3MDDv[kA{KM7:TR?= M4j4[|I{QDVyMUm5
Capan1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVe3NkBp NYPacXVlTE2VTx?= Mn71RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDCVmNCOiCpZX7lJI12fGG2ZXSgbJVu[W5iQ3HwZY4yKGOnbHzzJJdqfGhiSVO1NEBw\iB|OT63JO69VQ>? NIXG[IIzPDN7OEO4Ny=>
DT40 NUPtfJNpS3m2b4TvfIlkKEG|c3H5 MmPLO|IhcA>? NIq1NWtFVVOR MVnDfZRwfG:6aXPpeJkh[WejaX7zeEBkcGmla3XuJGJTS0F{LXTl[olkcWWwdDDEWFQxKGOnbHzz M4PzZVI1QTJ{NUi3
ML-1 MYLBdI9xfG:2aXOgRZN{[Xl? M3r3VlIvPSEQvF2= NX7uW4xROjRiaB?= NVXNT5pYTE2VTx?= NHHNcHZUgW6ncnfpd5Rq[2GubImg[Y5p[W6lZYOgWHJCUUxvaX7keYNm\CCjcH;weI9{cXNiaX6gUWwuOSClZXzsdy=> NWLOSmN1OjR6OUWxN|U>
HCT-116 NXHTPXR6U2mwYYPlJGF{e2G7 MWmwMlUh|ryP NXXGS254OjRiaB?= M4i3dnBCWlBiYXP0bZZqfHliZHXjdoVie2W| NFj3RoYzOzB3NEKxNy=>
UM-SCC1 NF3mS2NEgXSxdH;4bYMhSXO|YYm= M2nvWlExKM7:TR?= NHqyVpIzPCCq MX7S[YR2[2W|IITo[UBk\WyuII\pZYJqdGm2eR?= NIO2RYgzOTlzMk[yNC=>
FaDu M{DabmN6fG:2b4jpZ{BCe3OjeR?= MmDyNVAh|ryP MXWyOEBp MUXS[YR2[2W|IITo[UBk\WyuII\pZYJqdGm2eR?= MlWzNlE6OTJ4MkC=
PC-3 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{C1OlExKM7:TR?= NHrJRVVKdmS3Y3XzJIEhe2mpbnnmbYNidnRiaX7obYJqfGmxbjDpckBkd2yxbomg[o9zdWG2aX;uxsA> M2fUS|IyPTdzOUGy
EoL-1-cell MmDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUL1TIdwUUN3ME2xMlA4QThizszN NITjOYVUSU6JRWK=
NCI-SNU-5 MoDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDtUnRKSzVyPUOuNVI5PDFizszN M2\qWHNCVkeHUh?=
BV-173 M{LIUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DFOWlEPTB;NT60OVQxQSEQvF2= MlXGV2FPT0WU
HCC1806 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTjTWM2OD13Lke1NVc{KM7:TR?= M3HEPHNCVkeHUh?=
COLO-680 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUP0OWt5UUN3ME22MlIyPDB4IN88US=> MkPyV2FPT0WU
HCC2218 M1LFUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjKSYpNUUN3ME23Mlc6PzB2IN88US=> NFrGdFJUSU6JRWK=
SK-MEL-24 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrtOohKSzVyPUeuPFE6OjRizszN NIXRTJVUSU6JRWK=
NCI-H720 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRThwNEO2NFMh|ryP MWLTRW5ITVJ?
KASUMI-1 MnTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPRWYhKSzVyPUiuPFkzPjZizszN NUD6NFR{W0GQR1XS
HAL-01 Mlm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PXcGlEPTB;OT64PFYzKM7:TR?= MlPsV2FPT0WU
CAL-33 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPjPINKSzVyPUGwMlQ{PCEQvF2= MYnTRW5ITVJ?
SK-MEL-1 NW\6PIV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HjN2lEPTB;MUKuOFY3OyEQvF2= NX3aVYpnW0GQR1XS
Ramos-2G6-4C10 NWjHTZpwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVO2RoI2UUN3ME2xNk41PzV{IN88US=> M4f2NHNCVkeHUh?=
KY821 NILvbJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUKyfG5wUUN3ME2xNk41QDVizszN MWLTRW5ITVJ?
HEC-1 NVLJRmJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTF{LkmxPVYh|ryP NX[yNYVOW0GQR1XS
SK-NEP-1 NIjyS2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTF|LkG2OkDPxE1? MVPTRW5ITVJ?
MN-60 M37Ybmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTF|LkWzPFkh|ryP NYe1U4tpW0GQR1XS
DU-145 NWX0XlVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\Dc5NKSzVyPUGzMlkxPTNizszN M1nOfnNCVkeHUh?=
EW-3 M3;UfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzCRXl1UUN3ME2xOE42PTZ3IN88US=> MXrTRW5ITVJ?
OS-RC-2 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXi2UZhrUUN3ME2xOU46PTh7IN88US=> MVLTRW5ITVJ?
RPMI-8226 MmLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1eyU2lEPTB;MU[uNlA1OiEQvF2= M1HuPHNCVkeHUh?=
ChaGo-K-1 NVLvT5ByT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjLeW9rUUN3ME2xOk42OzJ3IN88US=> NVf4bpJOW0GQR1XS
DEL MkjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjNfZZKSzVyPUG2MlY4OTdizszN NWPrZ5R3W0GQR1XS
GP5d Mn\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rRPWlEPTB;MUeuNFU{KM7:TR?= NF3FU2hUSU6JRWK=
COLO-668 Mkf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIq4OnVKSzVyPUG3MlYzQTRizszN M3jN[3NCVkeHUh?=
H9 NYLIZll5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTF6LkK4N|Mh|ryP NW\UR5NRW0GQR1XS
NKM-1 M1\WOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7ETWM2OD1zOD61NVE6KM7:TR?= MVHTRW5ITVJ?
KYSE-150 M3TVOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFqyU21KSzVyPUG4Mlk6QDZizszN MkLLV2FPT0WU
Daoy NET3[mhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEG1WZVKSzVyPUG5MlU3PDlizszN NVWxS2RWW0GQR1XS
ECC10 M3PPRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTJyLke0OVUh|ryP NWKzSXNxW0GQR1XS
A388 NI\qeZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHm[mFTUUN3ME2yNU46ODlzIN88US=> MljGV2FPT0WU
MHH-NB-11 M3rKXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTJ|LkGzOlMh|ryP MUPTRW5ITVJ?
HCC1937 MnrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml74TWM2OD1{ND63OFYh|ryP MnjPV2FPT0WU
TGBC11TKB MkC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrIZ|RCUUN3ME2yOU43QDZ|IN88US=> NX7BN4VDW0GQR1XS
CTV-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4L3[mlEPTB;MkWuPFk3QSEQvF2= M2LST3NCVkeHUh?=
NCI-H2029 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPZOopCUUN3ME2yOk41OjN6IN88US=> MW\TRW5ITVJ?
HLE MmHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTJ5LkC1OEDPxE1? NIPkW2lUSU6JRWK=
NCI-H1693 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHKXWo3UUN3ME2yO{4zQDl6IN88US=> MX;TRW5ITVJ?
HCC70 NILKZVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITFb3RKSzVyPUK3MlczPDZizszN M{\LN3NCVkeHUh?=
BEN MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm[4TWM2OD1{Nz65OVY3KM7:TR?= M3PrUHNCVkeHUh?=
LB771 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUm2bVRnUUN3ME2yPE45Ozd|IN88US=> NYPIbGxYW0GQR1XS
697 NX3UeZBzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVGxbFlIUUN3ME2yPU4xOjN3IN88US=> MnLQV2FPT0WU
LU-139 NG\0enVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHi5XHNKSzVyPUK5MlM4PDhizszN M4rzRnNCVkeHUh?=
EW-13 Mk\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XmVGlEPTB;MkmuN|gyPCEQvF2= M1LyRXNCVkeHUh?=
MOLT-13 M3rZemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUn4d3RnUUN3ME2yPU4{QDF2IN88US=> NWD1cY1nW0GQR1XS
L-363 NFjsfXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIW1RYVKSzVyPUK5MlQ4QThizszN MknzV2FPT0WU
EM-2 NWTjNm9WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorDTWM2OD1{OT60PVAyKM7:TR?= NX[1cmt1W0GQR1XS
RS4-11 MlW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTNyLkSyOFEh|ryP NG\xUJlUSU6JRWK=
A2780 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTNyLke0OVch|ryP MoDrV2FPT0WU
KU812 MmHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPWTWM2OD1|Mj6zOlQzKM7:TR?= MYHTRW5ITVJ?
COLO-684 NWLXNGlzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHmTWM2OD1|Mz6zOVk6KM7:TR?= NHvldnBUSU6JRWK=
MFE-280 MlLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPNeGNQUUN3ME2zN{4{QDh7IN88US=> MYnTRW5ITVJ?
KG-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXFTWM2OD1|Mz62NFAyKM7:TR?= MYHTRW5ITVJ?
JVM-3 NX;yOWRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4S5e2lEPTB;M{WuOVg3QCEQvF2= NFjlOmtUSU6JRWK=
MV-4-11 NUXZfXdwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTN3Lki0PVkh|ryP NYWxOpFsW0GQR1XS
LAMA-84 MkDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvzU21QUUN3ME2zOk44OzR3IN88US=> MUHTRW5ITVJ?
MOLT-16 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XmTmlEPTB;M{[uPVUzKM7:TR?= MVnTRW5ITVJ?
H4 M{HxRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4D2V2lEPTB;M{euOVY4KM7:TR?= MXzTRW5ITVJ?
T47D M{LLd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTN5LkewNVgh|ryP NVL4R3hZW0GQR1XS
CAL-54 NG\xSWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTN5Lkm2OkDPxE1? MnfFV2FPT0WU
SW982 NGXjOmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TERmlEPTB;M{iuNFk6QCEQvF2= MWHTRW5ITVJ?
IGROV-1 M1Tlbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDDTXFKSzVyPUO5MlM{ODRizszN MoXSV2FPT0WU
NB14 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2naNWlEPTB;NECuO|A{OSEQvF2= MniwV2FPT0WU
HCC1187 NYr6[WQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4myc2lEPTB;NEGuNlc4OSEQvF2= NWW1UoNiW0GQR1XS
SBC-1 NHnGTWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTRzLkOwOlMh|ryP MV7TRW5ITVJ?
KARPAS-45 NEnXbmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTRzLkS4NVgh|ryP NIC3UZJUSU6JRWK=
MOLT-4 MmXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvOO2RKUUN3ME20Nk4zPTN6IN88US=> MkXuV2FPT0WU
JVM-2 NELabZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfnTWM2OD12Mj65NlA4KM7:TR?= MVnTRW5ITVJ?
A4-Fuk NG\4cXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTR|LkW2PVEh|ryP MWfTRW5ITVJ?
MDA-MB-361 NGj1[mJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUm1fZZXUUN3ME20N{45PDF2IN88US=> NX;vcmVpW0GQR1XS
BALL-1 Ml3KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofaTWM2OD12Mz65OVMzKM7:TR?= MofYV2FPT0WU
T98G MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTR2Lki1NVch|ryP NV3hPXFYW0GQR1XS
Mo-T M37QeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nYeGlEPTB;NEWuOlM5QSEQvF2= NEjI[2dUSU6JRWK=
MHH-PREB-1 NUDMZ|doT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjEeI5KSzVyPUS1Mlc2QDVizszN NYPuT284W0GQR1XS
ALL-PO NF63R2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTR5LkO3PVEh|ryP MnfUV2FPT0WU
NCI-H510A MnfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEizRnBKSzVyPUS3MlkxOzRizszN MlHPV2FPT0WU
ML-2 NFXHd29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nBc2lEPTB;NEmuO|g2PiEQvF2= MkPSV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-STAT3 / STAT3 / p-AKT(S473) / p-AKT(T308) / p-ERK / p-p38; 

PubMed: 22678161     


Effects of AG-014699, AZD-2281, ABT-888, or BSI-201 on the phosphorylation status of Stat3, Akt, ERK, and p38 in MDA-MB-468, MDA-MB-231, and Cal-51 cells after 72 h of treatment

22678161
Immunofluorescence
HuR; 

PubMed: 28687616     


Immunofluorescent images of HuR (green) in MIA PaCa-2 cells treated with PARPi for 12hr. Nuclei were stained with DAPI. Magnification 40X.

BRCA1; 

PubMed: 21917757     


Effects of ABT-888 and/or bortezomib on BRCA1 and RAD51 foci formation. BRCA1 and RAD1 foci induced by ABT-888 were completely resolved in cells cotreated with bortezomib. Image acquisition was performed with an epifluorescence microscope (BX51; Olympus) and multispectral color camera (Nuance FX; CRi) with a 60× or 100× magnification lens and oil immersion.

28687616 21917757
Growth inhibition assay
Cell viability (TNBC cell lines); 

PubMed: 27880910     


BRCA-proficient TNBC cell lines were treated with veliparib in the absence and presence of dinaciclib, demonstrating reduced IC50 values in the presence of dinaciclib.

Cell viability (melanoma cells); 

PubMed: 29956724     


Dose-dependent inhibitory effect of ABT-888 on melanoma cell proliferation. Human melanoma cell lines were exposed to diluents (control; CTRL) or increasing concentrations of ABT-888 for 72 h and their viability was assessed by MTT assay. Absorbance was detected at 540 nm with a microplate reader and data were expressed as a percentage of the CTRL. Data are the means ± SD of 3 experiments performed in triplicate. Statistical significance was calculated against the CTRL (*P<0.05; **P<0.01).

27880910 29956724
In vivo The oral bioavailability of ABT-888 is 56%-92% in mice, Sprague-Dawley rats, beagle dogs, and cynomolgus monkeys after oral administration. [1] ABT-888 (25 mg/kg i.p.) could improve tumor growth delay in a NCI-H460 xenograft model with well tolerated. Combination with radiation, ABT-888 decreases the tumor vessel formation. [3] ABT-888 reduces intratumor PAR levels by more than 95% at a dose of 3 and 12.5 mg/kg in A375 and Colo829 xenograft models and the suppression could be maintained over time. [4]

Protocol

Animal Research:

[1]

- Collapse
  • Animal Models: NCI-H460, H460, B16F10 and 9L xenografts in C57BL/6 mice
  • Dosages: ~25 mg/kg
  • Administration: Orally administered
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 17 mg/mL (69.58 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
0.5% methylcellulose+0.2% Tween 80
For best results, use promptly after mixing.
5 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 244.29
Formula

C13H16N4O

CAS No. 912444-00-9
Storage powder
in solvent
Synonyms NSC 737664
Smiles CC1(CCCN1)C2=NC3=C(C=CC=C3[NH]2)C(N)=O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03044795 Withdrawn Drug: Veliparib Cancer University Medical Center Groningen|AbbVie|Dutch Cancer Society November 2019 Phase 2
NCT02723864 Recruiting Drug: Veliparib + VX-970 + Cisplatin Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) August 9 2017 Phase 1
NCT02483104 Completed Drug: veliparib|Drug: carboplatin|Drug: paclitaxel Ovarian Cancer AbbVie July 2015 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Related PARP Products

Tags: buy Veliparib|Veliparib ic50|Veliparib price|Veliparib cost|Veliparib solubility dmso|Veliparib purchase|Veliparib manufacturer|Veliparib research buy|Veliparib order|Veliparib mouse|Veliparib chemical structure|Veliparib mw|Veliparib molecular weight|Veliparib datasheet|Veliparib supplier|Veliparib in vitro|Veliparib cell line|Veliparib concentration|Veliparib nmr|Veliparib in vivo|Veliparib clinical trial|Veliparib inhibitor|Veliparib DNA Damage inhibitor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID